This webinar, hosted by DDW and presented by Sartorius, will examine T cell exhaustion and how it is recognised as a major challenge in the development of immuno-oncology therapies.
A broad term used to describe the loss of effector function due to chronic antigen exposure, it commonly occurs within the tumour microenvironment, impairing the T cells’ ability to effectively eradicate cancerous cells.
Speaker Lauren Kelsey (pictured), a scientist in the iQue applications group, part of the European based BioAnalytics at Sartorius will discuss how the development of tumour-specific immunotherapies focuses on overcoming this exhausted phenotype of T cells to allow targeted killing of the tumour.
To listen to this free-to-attend webinar, which will take place on 22 October 2020 3:00 PM – 4:00 PM BST please sign up here (subject to approval).
Kelsey has been involved in the research and development of novel applications at Sartorius. She will examine the use of advanced flow cytometry to quantify T cell exhaustion phenotypes and cytokine release; how Bispecific T cell Engager (BiTE) antibodies in an immune cell killing assay affect T cell exhaustion and the influence of target cells on CAR-T cell exhaustion
Kelsey has been focussing on the iQue3 advanced flow cytometry platform where she has supported a number of the immuno-oncology campaigns that are used to exemplify how this technology can be applied to the drug discovery process.
She obtained a degree in Biology at the University of Bath and went on to complete a masters in Regenerative Medicine where she studiedmouse pancreatic and liver developmentbefore joining Sartorius as an Associate Scientist in 2018.
Date: 22 October 2020
Time: 3pm UK BST
Duration: 1 hour
Cost: Free-to-attend (participation subject to approval)
Click here to register for free